Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.
Saved in:
| Title: | Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. |
|---|---|
| Authors: | Patel K; Swedish Cancer Institute, Seattle, WA., Vose JM; Division of Hematology, University of Nebraska Medical Center, Omaha, NE., Nasta SD; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Brown JR; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Maddocks KJ; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Shah NN; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI., Fakhri B; Division of Hematology, Stanford University School of Medicine, Stanford, CA., Tessoulin B; Haematology Department, University Hospital of Nantes, Nantes, France., Ma S; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL., Jagadeesh D; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Lech-Maranda E; Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Coombs CC; Division of Hematology/Oncology, University of California Irvine, Irvine, CA., Patel MR; Florida Cancer Specialists, Sarasota, FL.; Sarah Cannon Research Institute, Nashville, TN., Rhodes JM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Ujjani C; Division of Hematology and Oncology, Fred Hutchinson Cancer Research Center, Seattle, WA., Hoffmann MS; The University of Kansas Cancer Center, Kansas City, MO., Cheah CY; Linear Clinical Research and Sir Charles Gairdner Hospital, Nedlands, WA, Australia., Munir T; Department of Haematology, St James's University Hospital, Leeds, United Kingdom., Lewis D; University Hospitals Plymouth NHS, Plymouth, United Kingdom., Scarfò L; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy., Eyre TA; Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom., Alencar A; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Cohen JB; Winship Cancer Institute, Emory University, Atlanta, GA., Zelenetz AD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Tsai DE; Eli Lilly and Company, Indianapolis, IN., Li M; Eli Lilly and Company, Indianapolis, IN., Bian Y; Eli Lilly and Company, Indianapolis, IN., Abada P; Eli Lilly and Company, Indianapolis, IN., Balbas M; Eli Lilly and Company, Indianapolis, IN., Zinzani PL; Istituto di Ematologia 'Seràgnoli,' Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy. |
| Source: | Blood advances [Blood Adv] 2026 Apr 14; Vol. 10 (7), pp. 2441-2451. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
